phase I clinical study Hummingbird Bioscience, Novogene Partner to ID Cancer Patients With NRG1 Fusions in China Novogene will use next-generation sequencing to identify solid tumor patients eligible to enroll in clinical trials of Hummingbird's anti-HER3 agent, HMBD-001. MapKure, Personalis Partner to Screen Patients for BRAF Inhibitor Trial Personalis plans to develop a companion diagnostic to MapKure's BRAF inhibitor, BGB-3245, once biomarkers have been identified in the study. Kronos Bio Doses First Patient in CDK9 Inhibitor Trial With Tempus Performing Sequencing Kronos is working with Tempus to sequence patients' tumor samples in the study for MYC amplification and overexpression. Merus, Sema4 Partner to Accelerate Enrollment in Zenocutuzumab Trial Sema4 will use its next-generation sequencing testing services to identify patients with solid tumors harboring NRG1 fusions for Merus' Phase I/II drug trial. Novellus, Tempus Partner to Enroll Patients in BRAF Inhibitor Clinical Trial Program The Jerusalem-based drug developer is studying PLX8394 in patients with BRAF V600-mutated gliomas and solid tumors with non-V600 mutations. Oct 6, 2020 BostonGene Collaborates With Transgene, NEC Corporation on Trials of Bespoke Cancer Vaccine Aug 13, 2020 Strata, Mirati Therapeutics Partner on Tumor-Agnostic Clinical Trial of Novel KRAS G12C Inhibitor Feb 11, 2020 Natera, Elicio Therapeutics Partner on Phase I/II Pancreatic Cancer Study May 16, 2019 Roche Drug Shows Benefit in Pediatric Patients With Rare, Molecularly Defined Tumors Premium Feb 9, 2015 New Data Shows Higher Dose of Regulus HCV Drug Offers Better Viral Load Reductions Premium Jan 12, 2012 Quark Releases Positive Phase I Data on Ocular Neuroprotectant Premium Jun 9, 2011 Alnylam Presents Phase I Data at ASCO Showing Liver Cancer Drug Well Tolerated Premium Jan 6, 2011 Alnylam Releases Phase I Data Showing Liver Cancer Drug Reaches Target Tissue, Triggers RNAi Premium Dec 16, 2010 Alnylam Data Shows 'Predictable Correlation' of Clinical, Preclinical Findings on Cancer Drug Premium Mar 25, 2010 Calando, CalTech Researchers Publish Phase I Data on siRNA Cancer Drug Premium Breaking News Enzo Biochem, CLX Health Partner to Support COVID-19 Testing for International Travel Type 1 Diabetes GWAS, Fine-Mapping Leads to New Genetic Loci, Potential Drug Targets LSU Health Sciences Center Wins $2.4M to Lead SARS-CoV-2 Variant Sequencing Program NanoString Technologies, Parker Institute for Cancer Immunotherapy Partner on Cell Therapy Project BGI Americas Collaborating With Champions Oncology on Proteomic Cancer Research Personal Genome Diagnostics Inks Cancer Genomic Profiling Deal with Duke University Health System The Scan Missed Early Cases A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports. Limited Journal Editor Diversity A survey finds low diversity among scientific and medical journal editors, according to The Scientist. How Much of a Threat? Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned. PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.